[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f8V14H5eaAU7ladseT_jQuT8EVLVwGXFn-AM5JOdOceA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"University Hospital, Tours",[4],303,false,70,33,189575,26,219,[14,17,20,22,25,27,29,32],{"name":15,"count":16},"Amyotrophic Lateral Sclerosis",7,{"name":18,"count":19},"Breast Cancer",6,{"name":21,"count":19},"Rheumatoid Arthritis",{"name":23,"count":24},"Autism Spectrum Disorder",5,{"name":26,"count":24},"Cystic Fibrosis",{"name":28,"count":24},"Alzheimer Disease",{"name":30,"count":31},"Depression",4,{"name":33,"count":34},"Cervical Cancer",3,[36,41,46,51,56,61,66,70,75,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06093269","Pharmacokinetics Study of Cefazolin in Hemodialysis (CEFAZODIAL)","2025-12","Blood samples",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05916963","Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Destruction of Kidney Stones With Laser","2026-04-03","Furosemide 40 mg",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06892951","CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia","2026-06","Caspofungin Acetate 50 MG",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT05596786","Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial","2026-07-16","Rituximab",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06382389","Efficacy of EMONO as an add-on Therapy to Conventional Antidepressants for the Treatment of Depressive Symptoms in Nursing-home Residents With Neurocognitive Disorders: a Randomized Controlled Trial-","2026-08","EMONO",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06349798","Early and Late Effects of Nefopam in Multimodal Analgesia After Total Hip Arthroplasty (NEFARTHRO)","2026-09","Nefopam",{"nctId":67,"briefTitle":68,"date":64,"intervention":69},"NCT04949633","Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening","Prostaglandins",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT07121621","PHArmaCokinetics of methYLphenidate in Adult Patients With Attention-Deficit \u002FHyperactivity Disorder","2026-09-02","PHArmacoKinetics of methYLphenidate in adult patients with ADHD: comparison between patients with and without OBesity.",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06104956","Weaning Protocol for High-flow Nasal Oxygen Therapy in Intensive Care","2027-02","HFNO weaning protocol",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT05385432","Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies","2027-03-01","Rabbit Anti thymocyte globulin",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,121,145,180,245,271,298,316,337,364,391,409,432,450,473,491,515,533,559,584,602,648,670,729,753,771,799,833,855,879,905,930,956,982,1010,1034,1068,1104,1129,1155,1181,1199,1226,1244,1271,1289,1314,1341,1359,1377,1404,1422,1447,1465,1483,1512,1530,1556,1580,1604,1630,1655,1684,1702,1720,1738,1756,1774,1792,1819,1837,1862,1887,1912,1930,1955,1982,2007,2030,2055,2091,2124,2149,2173,2198,2223,2248,2274,2292,2317,2342,2366,2384,2410,2428,2455,2481,2506,2524],{"intervention":94,"totalTrials":95,"cells":96},"Phenoxymethylpenicillin",1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":119},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":113},[108],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},"NCT07549594","Prophylaxis of Recurrent Erysipelas in Lower Limbs: compreSsion thErapy vs aNTibiotics and Compression Therapy.","NOT_YET_RECRUITING",[90],"2030-04-01","2026-04-01",200,[117],"Recurrent Erysipelas",[94],{"trials":120,"activeCount":99},[],{"intervention":74,"totalTrials":95,"cells":122},{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":129,"PHASE4":131,"NA":143},{"trials":124,"activeCount":99},[],{"trials":126,"activeCount":99},[],{"trials":128,"activeCount":99},[],{"trials":130,"activeCount":99},[],{"trials":132,"activeCount":95,"soonestReadout":73},[133],{"nctId":71,"briefTitle":72,"status":111,"phases":134,"primaryCompletion":73,"completion":73,"start":135,"enrollment":136,"conditions":137,"interventions":142},[90],"2025-09-01",30,[138,139,140,141],"Attention Deficit Hyperactivity Disorder (ADHD)","Obesity (Body Mass Index &Amp;Amp;gt;30 kg\u002Fm2)","Methylphenidate","Obesity &Amp; Overweight",[74],{"trials":144,"activeCount":99},[],{"intervention":40,"totalTrials":146,"cells":147},2,{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":167},{"trials":149,"activeCount":99},[],{"trials":151,"activeCount":99},[],{"trials":153,"activeCount":99},[],{"trials":155,"activeCount":99},[],{"trials":157,"activeCount":95,"soonestReadout":39},[158],{"nctId":37,"briefTitle":38,"status":159,"phases":160,"primaryCompletion":39,"completion":39,"start":161,"enrollment":162,"conditions":163,"interventions":166},"ACTIVE_NOT_RECRUITING",[90],"2023-11-20",32,[164,165],"Hemodialysis Catheter Infection","Infection, Bacterial",[40],{"trials":168,"activeCount":99},[169],{"nctId":170,"briefTitle":171,"status":172,"phases":173,"primaryCompletion":174,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":179},"NCT04879277","Study of Low-grade Systemic Inflammation in Adult Patients With Phenylketonuria","COMPLETED",[91],"2021-08-25","2021-05-26",40,[178],"Phenylketonuria",[40],{"intervention":55,"totalTrials":24,"cells":181},{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":241,"NA":243},{"trials":183,"activeCount":99},[],{"trials":185,"activeCount":99},[],{"trials":187,"activeCount":99},[],{"trials":189,"activeCount":146,"soonestReadout":54},[190,201,210,218,229],{"nctId":191,"briefTitle":192,"status":111,"phases":193,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":200},"NCT06549231","Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis",[89],"2028-05-15","2028-11-15","2024-11-15",102,[199],"Interstitial Lung Disease With Systemic Sclerosis",[55],{"nctId":202,"briefTitle":203,"status":172,"phases":204,"primaryCompletion":205,"completion":206,"start":207,"enrollment":8,"conditions":208,"interventions":209},"NCT02304354","Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)",[89],"2019-04-09","2019-12-18","2015-03-09",[21],[55],{"nctId":52,"briefTitle":53,"status":211,"phases":212,"primaryCompletion":54,"completion":54,"start":213,"enrollment":214,"conditions":215,"interventions":217},"RECRUITING",[89],"2023-01-16",126,[216],"Lung Diseases",[55],{"nctId":219,"briefTitle":220,"status":172,"phases":221,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":228},"NCT00645606","Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia",[89],"2014-02","2017-07","2007-12",542,[227],"Leukemia",[55],{"nctId":230,"briefTitle":231,"status":172,"phases":232,"primaryCompletion":233,"completion":234,"start":235,"enrollment":236,"conditions":237,"interventions":239},"NCT02990286","Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases",[89],"2019-07-24","2020-02-17","2017-01-20",122,[238],"Lung Disease, Interstitial",[55,240],"Mycophenolate Mofetil",{"trials":242,"activeCount":99},[],{"trials":244,"activeCount":99},[],{"intervention":246,"totalTrials":95,"cells":247},"Avastin, 25 Mg\u002FmL Intravenous Solution",{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":254,"PHASE4":267,"NA":269},{"trials":249,"activeCount":99},[],{"trials":251,"activeCount":99},[],{"trials":253,"activeCount":99},[],{"trials":255,"activeCount":95,"soonestReadout":260},[256],{"nctId":257,"briefTitle":258,"status":111,"phases":259,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":266},"NCT06642844","Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment",[89],"2028-10-30","2029-10-30","2024-10-30",244,[265],"Unresectable Metastatic Colorectal Cancer",[246],{"trials":268,"activeCount":99},[],{"trials":270,"activeCount":99},[],{"intervention":272,"totalTrials":95,"cells":273},"Antihypertensive algorithm",{"EARLY_PHASE1":274,"PHASE1":276,"PHASE2":278,"PHASE3":280,"PHASE4":294,"NA":296},{"trials":275,"activeCount":99},[],{"trials":277,"activeCount":99},[],{"trials":279,"activeCount":99},[],{"trials":281,"activeCount":95,"soonestReadout":286},[282],{"nctId":283,"briefTitle":284,"status":211,"phases":285,"primaryCompletion":286,"completion":286,"start":287,"enrollment":288,"conditions":289,"interventions":292},"NCT05732727","Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease",[89],"2029-03","2023-03-28",720,[290,291],"Chronic Kidney Disease(CKD)","Uncontrolled Hypertension",[272,293],"Standard of care",{"trials":295,"activeCount":99},[],{"trials":297,"activeCount":99},[],{"intervention":293,"totalTrials":95,"cells":299},{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":306,"PHASE4":312,"NA":314},{"trials":301,"activeCount":99},[],{"trials":303,"activeCount":99},[],{"trials":305,"activeCount":99},[],{"trials":307,"activeCount":95,"soonestReadout":286},[308],{"nctId":283,"briefTitle":284,"status":211,"phases":309,"primaryCompletion":286,"completion":286,"start":287,"enrollment":288,"conditions":310,"interventions":311},[89],[290,291],[272,293],{"trials":313,"activeCount":99},[],{"trials":315,"activeCount":99},[],{"intervention":45,"totalTrials":95,"cells":317},{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":322,"PHASE3":324,"PHASE4":333,"NA":335},{"trials":319,"activeCount":99},[],{"trials":321,"activeCount":99},[],{"trials":323,"activeCount":99},[],{"trials":325,"activeCount":95,"soonestReadout":44},[326],{"nctId":42,"briefTitle":43,"status":211,"phases":327,"primaryCompletion":44,"completion":44,"start":328,"enrollment":329,"conditions":330,"interventions":332},[89],"2024-01-04",374,[331],"Kidney Stone",[45],{"trials":334,"activeCount":99},[],{"trials":336,"activeCount":99},[],{"intervention":338,"totalTrials":95,"cells":339},"Experimental group: Patients will be treated with carvedilol.",{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":346,"PHASE4":360,"NA":362},{"trials":341,"activeCount":99},[],{"trials":343,"activeCount":99},[],{"trials":345,"activeCount":99},[],{"trials":347,"activeCount":95,"soonestReadout":352},[348],{"nctId":349,"briefTitle":350,"status":111,"phases":351,"primaryCompletion":352,"completion":353,"start":354,"enrollment":355,"conditions":356,"interventions":359},"NCT06263816","Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial",[89],"2027-07-17","2030-07-17","2025-06-17",290,[357,358],"Asymptomatic Cirrhosis","Clinically Significant Portal Hypertension",[338],{"trials":361,"activeCount":99},[],{"trials":363,"activeCount":99},[],{"intervention":365,"totalTrials":95,"cells":366},"Dexmedetomidine",{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":373,"PHASE4":387,"NA":389},{"trials":368,"activeCount":99},[],{"trials":370,"activeCount":99},[],{"trials":372,"activeCount":99},[],{"trials":374,"activeCount":95,"soonestReadout":379},[375],{"nctId":376,"briefTitle":377,"status":111,"phases":378,"primaryCompletion":379,"completion":380,"start":381,"enrollment":382,"conditions":383,"interventions":385},"NCT07542990","Impact on Delirium of the Use of DEXmedetomidine as First-line Sedation in PEDIAtric Intensive Care",[89],"2029-04-15","2029-08-15","2026-04-15",266,[384],"Delirium in the Intensive Care Unit",[365,386],"Midazolam",{"trials":388,"activeCount":99},[],{"trials":390,"activeCount":99},[],{"intervention":386,"totalTrials":95,"cells":392},{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":399,"PHASE4":405,"NA":407},{"trials":394,"activeCount":99},[],{"trials":396,"activeCount":99},[],{"trials":398,"activeCount":99},[],{"trials":400,"activeCount":95,"soonestReadout":379},[401],{"nctId":376,"briefTitle":377,"status":111,"phases":402,"primaryCompletion":379,"completion":380,"start":381,"enrollment":382,"conditions":403,"interventions":404},[89],[384],[365,386],{"trials":406,"activeCount":99},[],{"trials":408,"activeCount":99},[],{"intervention":65,"totalTrials":95,"cells":410},{"EARLY_PHASE1":411,"PHASE1":413,"PHASE2":415,"PHASE3":417,"PHASE4":428,"NA":430},{"trials":412,"activeCount":99},[],{"trials":414,"activeCount":99},[],{"trials":416,"activeCount":99},[],{"trials":418,"activeCount":95,"soonestReadout":64},[419],{"nctId":62,"briefTitle":63,"status":111,"phases":420,"primaryCompletion":64,"completion":421,"start":422,"enrollment":423,"conditions":424,"interventions":426},[89],"2027-04","2024-04",546,[425],"Total Hip Arthroplasty",[65,65,427],"NaCl 0.9%",{"trials":429,"activeCount":99},[],{"trials":431,"activeCount":99},[],{"intervention":427,"totalTrials":95,"cells":433},{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":438,"PHASE3":440,"PHASE4":446,"NA":448},{"trials":435,"activeCount":99},[],{"trials":437,"activeCount":99},[],{"trials":439,"activeCount":99},[],{"trials":441,"activeCount":95,"soonestReadout":64},[442],{"nctId":62,"briefTitle":63,"status":111,"phases":443,"primaryCompletion":64,"completion":421,"start":422,"enrollment":423,"conditions":444,"interventions":445},[89],[425],[65,65,427],{"trials":447,"activeCount":99},[],{"trials":449,"activeCount":99},[],{"intervention":84,"totalTrials":95,"cells":451},{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":458,"PHASE4":469,"NA":471},{"trials":453,"activeCount":99},[],{"trials":455,"activeCount":99},[],{"trials":457,"activeCount":99},[],{"trials":459,"activeCount":95,"soonestReadout":83},[460],{"nctId":81,"briefTitle":82,"status":111,"phases":461,"primaryCompletion":83,"completion":462,"start":463,"enrollment":263,"conditions":464,"interventions":467},[89],"2030-03-01","2023-09-12",[465,466],"Renal Transplant Rejection","Induction Therapy",[84,468],"Basiliximab",{"trials":470,"activeCount":99},[],{"trials":472,"activeCount":99},[],{"intervention":468,"totalTrials":95,"cells":474},{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":479,"PHASE3":481,"PHASE4":487,"NA":489},{"trials":476,"activeCount":99},[],{"trials":478,"activeCount":99},[],{"trials":480,"activeCount":99},[],{"trials":482,"activeCount":95,"soonestReadout":83},[483],{"nctId":81,"briefTitle":82,"status":111,"phases":484,"primaryCompletion":83,"completion":462,"start":463,"enrollment":263,"conditions":485,"interventions":486},[89],[465,466],[84,468],{"trials":488,"activeCount":99},[],{"trials":490,"activeCount":99},[],{"intervention":69,"totalTrials":95,"cells":492},{"EARLY_PHASE1":493,"PHASE1":495,"PHASE2":497,"PHASE3":499,"PHASE4":511,"NA":513},{"trials":494,"activeCount":99},[],{"trials":496,"activeCount":99},[],{"trials":498,"activeCount":99},[],{"trials":500,"activeCount":95,"soonestReadout":64},[501],{"nctId":67,"briefTitle":68,"status":211,"phases":502,"primaryCompletion":64,"completion":503,"start":504,"enrollment":505,"conditions":506,"interventions":509},[89],"2026-11","2021-09-28",1494,[507,508],"Cervical Ripening","Unfavorable Cervix",[69,510],"Oxytocin",{"trials":512,"activeCount":99},[],{"trials":514,"activeCount":99},[],{"intervention":510,"totalTrials":95,"cells":516},{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":523,"PHASE4":529,"NA":531},{"trials":518,"activeCount":99},[],{"trials":520,"activeCount":99},[],{"trials":522,"activeCount":99},[],{"trials":524,"activeCount":95,"soonestReadout":64},[525],{"nctId":67,"briefTitle":68,"status":211,"phases":526,"primaryCompletion":64,"completion":503,"start":504,"enrollment":505,"conditions":527,"interventions":528},[89],[507,508],[69,510],{"trials":530,"activeCount":99},[],{"trials":532,"activeCount":99},[],{"intervention":534,"totalTrials":95,"cells":535},"Propranolol, 120mg",{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":553,"PHASE4":555,"NA":557},{"trials":537,"activeCount":99},[],{"trials":539,"activeCount":99},[],{"trials":541,"activeCount":95,"soonestReadout":546},[542],{"nctId":543,"briefTitle":544,"status":111,"phases":545,"primaryCompletion":546,"completion":547,"start":548,"enrollment":549,"conditions":550,"interventions":552},"NCT07452978","Propranolol for Early Secondary Prevention of Post-Traumatic Stress Disorder in Women Victims of Sexual Violence",[88],"2027-10-06","2028-03-01","2026-09-01",34,[551],"PTSD - Post Traumatic Stress Disorder",[534],{"trials":554,"activeCount":99},[],{"trials":556,"activeCount":99},[],{"trials":558,"activeCount":99},[],{"intervention":50,"totalTrials":95,"cells":560},{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":565,"PHASE3":578,"PHASE4":580,"NA":582},{"trials":562,"activeCount":99},[],{"trials":564,"activeCount":99},[],{"trials":566,"activeCount":95,"soonestReadout":49},[567],{"nctId":47,"briefTitle":48,"status":111,"phases":568,"primaryCompletion":49,"completion":569,"start":570,"enrollment":571,"conditions":572,"interventions":576},[87,88],"2028-12","2025-06",100,[573,574,575],"Pneumocystis Pneumonia","Pneumocystis Jirovecii Infection","Pneumocystis Infections",[50,577],"Physiologic saline",{"trials":579,"activeCount":99},[],{"trials":581,"activeCount":99},[],{"trials":583,"activeCount":99},[],{"intervention":577,"totalTrials":95,"cells":585},{"EARLY_PHASE1":586,"PHASE1":588,"PHASE2":590,"PHASE3":596,"PHASE4":598,"NA":600},{"trials":587,"activeCount":99},[],{"trials":589,"activeCount":99},[],{"trials":591,"activeCount":95,"soonestReadout":49},[592],{"nctId":47,"briefTitle":48,"status":111,"phases":593,"primaryCompletion":49,"completion":569,"start":570,"enrollment":571,"conditions":594,"interventions":595},[87,88],[573,574,575],[50,577],{"trials":597,"activeCount":99},[],{"trials":599,"activeCount":99},[],{"trials":601,"activeCount":99},[],{"intervention":603,"totalTrials":34,"cells":604},"Medical air",{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":630,"PHASE4":632,"NA":634},{"trials":606,"activeCount":99},[],{"trials":608,"activeCount":99},[],{"trials":610,"activeCount":95,"soonestReadout":59},[611,618],{"nctId":57,"briefTitle":58,"status":111,"phases":612,"primaryCompletion":59,"completion":59,"start":613,"enrollment":614,"conditions":615,"interventions":617},[88],"2024-06",96,[30,616],"Neurocognitive Disorders",[60,603],{"nctId":619,"briefTitle":620,"status":621,"phases":622,"primaryCompletion":39,"completion":623,"start":613,"enrollment":136,"conditions":624,"interventions":628},"NCT06430489","Treatment of Suicidal Ideation in the Emergency Department Using Nitrous Oxide","UNKNOWN",[88],"2026-01",[625,626,627],"Suicidal Ideation","Emergency Psychiatric","Nitrous Oxide",[629,603],"Nitrous oxide",{"trials":631,"activeCount":99},[],{"trials":633,"activeCount":99},[],{"trials":635,"activeCount":99},[636],{"nctId":637,"briefTitle":638,"status":172,"phases":639,"primaryCompletion":640,"completion":640,"start":641,"enrollment":642,"conditions":643,"interventions":646},"NCT05007028","Nitrous Oxide for Late-Life Depression - PROTO-BRAIN",[91],"2024-12-19","2021-11-16",60,[644,645],"Late-Life Depression","Resistant Depression, Treatment",[60,647],"Medical Air",{"intervention":60,"totalTrials":146,"cells":649},{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":654,"PHASE3":660,"PHASE4":662,"NA":664},{"trials":651,"activeCount":99},[],{"trials":653,"activeCount":99},[],{"trials":655,"activeCount":95,"soonestReadout":59},[656],{"nctId":57,"briefTitle":58,"status":111,"phases":657,"primaryCompletion":59,"completion":59,"start":613,"enrollment":614,"conditions":658,"interventions":659},[88],[30,616],[60,603],{"trials":661,"activeCount":99},[],{"trials":663,"activeCount":99},[],{"trials":665,"activeCount":99},[666],{"nctId":637,"briefTitle":638,"status":172,"phases":667,"primaryCompletion":640,"completion":640,"start":641,"enrollment":642,"conditions":668,"interventions":669},[91],[644,645],[60,647],{"intervention":671,"totalTrials":31,"cells":672},"Blood sample",{"EARLY_PHASE1":673,"PHASE1":675,"PHASE2":677,"PHASE3":679,"PHASE4":681,"NA":683},{"trials":674,"activeCount":99},[],{"trials":676,"activeCount":99},[],{"trials":678,"activeCount":99},[],{"trials":680,"activeCount":99},[],{"trials":682,"activeCount":99},[],{"trials":684,"activeCount":95,"soonestReadout":689},[685,697,709,721],{"nctId":686,"briefTitle":687,"status":211,"phases":688,"primaryCompletion":689,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":696},"NCT05859191","Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus",[],"2027-07","2030-07","2023-07-21",50,[694,695],"Systemic Lupus Erythematosus","Physiopathology",[671],{"nctId":698,"briefTitle":699,"status":172,"phases":700,"primaryCompletion":701,"completion":702,"start":703,"enrollment":9,"conditions":704,"interventions":708},"NCT04662996","Search for Predictive Factors of Resistance to Treatment for Metastatic Castration-resistant Prostate Cancer by Studying the Expression of microRNAs",[91],"2022-11-30","2023-11-30","2021-06-23",[705,706,707],"Prostate Cancer","Resistance, Disease","MicroRNAs",[671],{"nctId":710,"briefTitle":711,"status":172,"phases":712,"primaryCompletion":713,"completion":714,"start":715,"enrollment":716,"conditions":717,"interventions":720},"NCT05562141","Oxidative Stress in the Patient With Peroperative Analgesia by Intravenous Lidocaine",[],"2023-07-17","2023-07-18","2022-11-22",20,[718,719],"Oxidative Stress","Analgesia",[671],{"nctId":722,"briefTitle":723,"status":621,"phases":724,"primaryCompletion":725,"completion":725,"start":726,"enrollment":642,"conditions":727,"interventions":728},"NCT06230562","DIAGALS: Relation Between Tar DNA Binding Protein(TDP)-43 et Nrf-2 in ALS: a Track to Improve Diagnosis and Prognosis of the Disease",[91],"2025-08","2024-02",[15],[671,671],{"intervention":79,"totalTrials":95,"cells":730},{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":737,"PHASE4":739,"NA":741},{"trials":732,"activeCount":99},[],{"trials":734,"activeCount":99},[],{"trials":736,"activeCount":99},[],{"trials":738,"activeCount":99},[],{"trials":740,"activeCount":99},[],{"trials":742,"activeCount":95,"soonestReadout":78},[743],{"nctId":76,"briefTitle":77,"status":211,"phases":744,"primaryCompletion":78,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":751},[91],"2027-03","2024-02-17",370,[749,750],"Acute Hypoxemic Respiratory Failure","High-flow Nasal Oxygen Therapy",[79,752],"HFNO Standard of care",{"intervention":752,"totalTrials":95,"cells":754},{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":761,"PHASE4":763,"NA":765},{"trials":756,"activeCount":99},[],{"trials":758,"activeCount":99},[],{"trials":760,"activeCount":99},[],{"trials":762,"activeCount":99},[],{"trials":764,"activeCount":99},[],{"trials":766,"activeCount":95,"soonestReadout":78},[767],{"nctId":76,"briefTitle":77,"status":211,"phases":768,"primaryCompletion":78,"completion":745,"start":746,"enrollment":747,"conditions":769,"interventions":770},[91],[749,750],[79,752],{"intervention":772,"totalTrials":95,"cells":773},"Injection of iohexol for glomerular filtration rate (GFR) measurement",{"EARLY_PHASE1":774,"PHASE1":776,"PHASE2":778,"PHASE3":780,"PHASE4":782,"NA":784},{"trials":775,"activeCount":99},[],{"trials":777,"activeCount":99},[],{"trials":779,"activeCount":99},[],{"trials":781,"activeCount":99},[],{"trials":783,"activeCount":99},[],{"trials":785,"activeCount":95,"soonestReadout":790},[786],{"nctId":787,"briefTitle":788,"status":211,"phases":789,"primaryCompletion":790,"completion":790,"start":791,"enrollment":571,"conditions":792,"interventions":798},"NCT07246265","Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care",[91],"2028-09","2026-03-05",[793,794,795,796,797],"Sickle Cell Disease","Glomerular Hyperfiltration","Sickle Cell Nephropathy","Vaso-Occlusive Crises","Acute Chest Syndrome",[772],{"intervention":800,"totalTrials":146,"cells":801},"Tacrolimus targeted half-dose",{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":808,"PHASE4":810,"NA":831},{"trials":803,"activeCount":99},[],{"trials":805,"activeCount":99},[],{"trials":807,"activeCount":99},[],{"trials":809,"activeCount":99},[],{"trials":811,"activeCount":99},[812,823],{"nctId":813,"briefTitle":814,"status":621,"phases":815,"primaryCompletion":816,"completion":816,"start":817,"enrollment":818,"conditions":819,"interventions":821},"NCT02154854","Prospective Study to Measure Vascular Parameters (Ancillary Study of ADEQUATE)",[90],"2015-03","2013-07",104,[820],"De Novo Transplant Disease",[800,822],"Tacrolimus targeted plain dose",{"nctId":824,"briefTitle":825,"status":621,"phases":826,"primaryCompletion":816,"completion":816,"start":827,"enrollment":828,"conditions":829,"interventions":830},"NCT01744470","Efficacy and Safety Study of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus(ADEQUATE)",[90],"2012-05",286,[820],[800,822],{"trials":832,"activeCount":99},[],{"intervention":822,"totalTrials":146,"cells":834},{"EARLY_PHASE1":835,"PHASE1":837,"PHASE2":839,"PHASE3":841,"PHASE4":843,"NA":853},{"trials":836,"activeCount":99},[],{"trials":838,"activeCount":99},[],{"trials":840,"activeCount":99},[],{"trials":842,"activeCount":99},[],{"trials":844,"activeCount":99},[845,849],{"nctId":813,"briefTitle":814,"status":621,"phases":846,"primaryCompletion":816,"completion":816,"start":817,"enrollment":818,"conditions":847,"interventions":848},[90],[820],[800,822],{"nctId":824,"briefTitle":825,"status":621,"phases":850,"primaryCompletion":816,"completion":816,"start":827,"enrollment":828,"conditions":851,"interventions":852},[90],[820],[800,822],{"trials":854,"activeCount":99},[],{"intervention":856,"totalTrials":95,"cells":857},"Pulmozyme",{"EARLY_PHASE1":858,"PHASE1":860,"PHASE2":862,"PHASE3":864,"PHASE4":866,"NA":877},{"trials":859,"activeCount":99},[],{"trials":861,"activeCount":99},[],{"trials":863,"activeCount":99},[],{"trials":865,"activeCount":99},[],{"trials":867,"activeCount":99},[868],{"nctId":869,"briefTitle":870,"status":172,"phases":871,"primaryCompletion":872,"completion":872,"start":873,"enrollment":874,"conditions":875,"interventions":876},"NCT00843817","RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum",[90],"2013-04","2009-04",15,[26],[856],{"trials":878,"activeCount":99},[],{"intervention":880,"totalTrials":95,"cells":881},"Aspirin",{"EARLY_PHASE1":882,"PHASE1":884,"PHASE2":886,"PHASE3":888,"PHASE4":890,"NA":903},{"trials":883,"activeCount":99},[],{"trials":885,"activeCount":99},[],{"trials":887,"activeCount":99},[],{"trials":889,"activeCount":99},[],{"trials":891,"activeCount":99},[892],{"nctId":893,"briefTitle":894,"status":172,"phases":895,"primaryCompletion":896,"completion":896,"start":897,"enrollment":898,"conditions":899,"interventions":902},"NCT01729468","Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers",[90],"2016-10-25","2012-06-27",1106,[900,901],"Pre-eclampsia","Intra-uterine Growth Restriction",[880],{"trials":904,"activeCount":99},[],{"intervention":906,"totalTrials":95,"cells":907},"Atrovent + Bricanyl or Atrovent + Ventoline",{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":914,"PHASE4":916,"NA":928},{"trials":909,"activeCount":99},[],{"trials":911,"activeCount":99},[],{"trials":913,"activeCount":99},[],{"trials":915,"activeCount":99},[],{"trials":917,"activeCount":99},[918],{"nctId":919,"briefTitle":920,"status":172,"phases":921,"primaryCompletion":922,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":927},"NCT02103374","Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State",[90],"2015-12","2012-01",45,[926],"Severe Chronic Obstructive Pulmonary Disease",[906],{"trials":929,"activeCount":99},[],{"intervention":931,"totalTrials":95,"cells":932},"Weekly Oral Cyclic Antibiotic programme",{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":937,"PHASE3":939,"PHASE4":941,"NA":954},{"trials":934,"activeCount":99},[],{"trials":936,"activeCount":99},[],{"trials":938,"activeCount":99},[],{"trials":940,"activeCount":99},[],{"trials":942,"activeCount":99},[943],{"nctId":944,"briefTitle":945,"status":172,"phases":946,"primaryCompletion":947,"completion":948,"start":949,"enrollment":924,"conditions":950,"interventions":953},"NCT01388413","Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder",[90],"2016-01","2017-02","2011-08",[951,952],"Neurogenic Bladder","Urinary Tract Infection",[931],{"trials":955,"activeCount":99},[],{"intervention":957,"totalTrials":95,"cells":958},"Methotrexate",{"EARLY_PHASE1":959,"PHASE1":961,"PHASE2":963,"PHASE3":965,"PHASE4":967,"NA":980},{"trials":960,"activeCount":99},[],{"trials":962,"activeCount":99},[],{"trials":964,"activeCount":99},[],{"trials":966,"activeCount":99},[],{"trials":968,"activeCount":99},[969],{"nctId":970,"briefTitle":971,"status":172,"phases":972,"primaryCompletion":973,"completion":973,"start":974,"enrollment":975,"conditions":976,"interventions":978},"NCT01895764","Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)",[90],"2015-04-27","2013-03-20",110,[977],"Ankylosing Spondylitis",[979,957],"Adalimumab",{"trials":981,"activeCount":99},[],{"intervention":983,"totalTrials":95,"cells":984},"Influenza Vaccination",{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":991,"PHASE4":993,"NA":1008},{"trials":986,"activeCount":99},[],{"trials":988,"activeCount":99},[],{"trials":990,"activeCount":99},[],{"trials":992,"activeCount":99},[],{"trials":994,"activeCount":99},[995],{"nctId":996,"briefTitle":997,"status":172,"phases":998,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":1002,"conditions":1003,"interventions":1007},"NCT06508437","Effect of Influenza Vaccination on Global Systemic Inflammatory Markers in Patients With Stable Coronary Artery Disease",[90],"2024-10-31","2024-11-25","2024-10-21",47,[1004,1005,1006],"Coronary Artery Disease","Inflammatory Response","Atherosclerosis",[983],{"trials":1009,"activeCount":99},[],{"intervention":1011,"totalTrials":95,"cells":1012},"Genetic analysis",{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1017,"PHASE3":1019,"PHASE4":1021,"NA":1032},{"trials":1014,"activeCount":99},[],{"trials":1016,"activeCount":99},[],{"trials":1018,"activeCount":99},[],{"trials":1020,"activeCount":99},[],{"trials":1022,"activeCount":99},[1023],{"nctId":1024,"briefTitle":1025,"status":172,"phases":1026,"primaryCompletion":1027,"completion":1027,"start":1028,"enrollment":1029,"conditions":1030,"interventions":1031},"NCT00308893","BDNF Gene Polymorphism and Antidepressants Treatment",[90],"2012-06","2006-07",188,[30],[1011],{"trials":1033,"activeCount":99},[],{"intervention":1035,"totalTrials":146,"cells":1036},"MabThera",{"EARLY_PHASE1":1037,"PHASE1":1039,"PHASE2":1041,"PHASE3":1043,"PHASE4":1064,"NA":1066},{"trials":1038,"activeCount":99},[],{"trials":1040,"activeCount":99},[],{"trials":1042,"activeCount":99},[],{"trials":1044,"activeCount":99},[1045,1056],{"nctId":1046,"briefTitle":1047,"status":621,"phases":1048,"primaryCompletion":1049,"completion":1049,"start":1050,"enrollment":1051,"conditions":1052,"interventions":1054},"NCT01066689","Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation",[89],"2011-10","2008-10",64,[1053],"Graft Rejection",[1035,1055],"Physiological serum",{"nctId":1057,"briefTitle":1047,"status":172,"phases":1058,"primaryCompletion":1059,"completion":1059,"start":1050,"enrollment":176,"conditions":1060,"interventions":1062},"NCT01350882",[89],"2012-10",[1061],"Humoral Rejection in Kidney Transplantation",[1035,1063],"Physiological serum : sodium chloride, sodium citrate",{"trials":1065,"activeCount":99},[],{"trials":1067,"activeCount":99},[],{"intervention":1069,"totalTrials":146,"cells":1070},"Hydrocortisone",{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1075,"PHASE3":1077,"PHASE4":1100,"NA":1102},{"trials":1072,"activeCount":99},[],{"trials":1074,"activeCount":99},[],{"trials":1076,"activeCount":99},[],{"trials":1078,"activeCount":99},[1079,1090],{"nctId":1080,"briefTitle":1081,"status":172,"phases":1082,"primaryCompletion":1083,"completion":1084,"start":1085,"enrollment":1086,"conditions":1087,"interventions":1089},"NCT02517489","Community-Acquired Pneumonia : Evaluation of Corticosteroids",[89],"2020-07-19","2020-08-28","2015-10-28",952,[1088],"Community Acquired Pneumonia",[1069],{"nctId":1091,"briefTitle":1092,"status":1093,"phases":1094,"primaryCompletion":1095,"completion":1095,"start":1095,"enrollment":99,"conditions":1096,"interventions":1098},"NCT04359511","Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia","WITHDRAWN",[89],"2020-07-03",[1097],"COVID-19",[1099,1069],"Prednisone",{"trials":1101,"activeCount":99},[],{"trials":1103,"activeCount":99},[],{"intervention":1105,"totalTrials":95,"cells":1106},"Pharmacological cervical ripening",{"EARLY_PHASE1":1107,"PHASE1":1109,"PHASE2":1111,"PHASE3":1113,"PHASE4":1125,"NA":1127},{"trials":1108,"activeCount":99},[],{"trials":1110,"activeCount":99},[],{"trials":1112,"activeCount":99},[],{"trials":1114,"activeCount":99},[1115],{"nctId":1116,"briefTitle":1117,"status":172,"phases":1118,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":1121,"conditions":1122,"interventions":1124},"NCT02907060","Mechanical cervicAl ripeninG for Women With PrOlongedPregnancies",[89],"2018-12-12","2017-01-27",1224,[1123],"Prolonged Pregnancy",[1105],{"trials":1126,"activeCount":99},[],{"trials":1128,"activeCount":99},[],{"intervention":1130,"totalTrials":95,"cells":1131},"Rivaroxaban",{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1138,"PHASE4":1151,"NA":1153},{"trials":1133,"activeCount":99},[],{"trials":1135,"activeCount":99},[],{"trials":1137,"activeCount":99},[],{"trials":1139,"activeCount":99},[1140],{"nctId":1141,"briefTitle":1142,"status":621,"phases":1143,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1147,"conditions":1148,"interventions":1150},"NCT05410275","Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients",[89],"2023-12-01","2024-01-01","2022-12-01",10,[1149],"Chronic Hemodialysis Patients",[1130],{"trials":1152,"activeCount":99},[],{"trials":1154,"activeCount":99},[],{"intervention":1156,"totalTrials":95,"cells":1157},"Methotrexate (Novatrex ®) + anti-H1",{"EARLY_PHASE1":1158,"PHASE1":1160,"PHASE2":1162,"PHASE3":1164,"PHASE4":1177,"NA":1179},{"trials":1159,"activeCount":99},[],{"trials":1161,"activeCount":99},[],{"trials":1163,"activeCount":99},[],{"trials":1165,"activeCount":99},[1166],{"nctId":1167,"briefTitle":1168,"status":172,"phases":1169,"primaryCompletion":1170,"completion":1171,"start":1172,"enrollment":1173,"conditions":1174,"interventions":1176},"NCT01960283","Methotrexate in the Treatment of Chronic Idiopathic Urticaria",[89],"2016-03","2016-05","2011-11",83,[1175],"Chronic Urticaria",[1156],{"trials":1178,"activeCount":99},[],{"trials":1180,"activeCount":99},[],{"intervention":1055,"totalTrials":95,"cells":1182},{"EARLY_PHASE1":1183,"PHASE1":1185,"PHASE2":1187,"PHASE3":1189,"PHASE4":1195,"NA":1197},{"trials":1184,"activeCount":99},[],{"trials":1186,"activeCount":99},[],{"trials":1188,"activeCount":99},[],{"trials":1190,"activeCount":99},[1191],{"nctId":1046,"briefTitle":1047,"status":621,"phases":1192,"primaryCompletion":1049,"completion":1049,"start":1050,"enrollment":1051,"conditions":1193,"interventions":1194},[89],[1053],[1035,1055],{"trials":1196,"activeCount":99},[],{"trials":1198,"activeCount":99},[],{"intervention":1200,"totalTrials":95,"cells":1201},"Levofloxacin",{"EARLY_PHASE1":1202,"PHASE1":1204,"PHASE2":1206,"PHASE3":1208,"PHASE4":1222,"NA":1224},{"trials":1203,"activeCount":99},[],{"trials":1205,"activeCount":99},[],{"trials":1207,"activeCount":99},[],{"trials":1209,"activeCount":99},[1210],{"nctId":1211,"briefTitle":1212,"status":172,"phases":1213,"primaryCompletion":1214,"completion":1215,"start":1216,"enrollment":1217,"conditions":1218,"interventions":1220},"NCT02701608","Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus",[89],"2024-08-15","2024-12-04","2016-02-29",162,[1219],"Infective Endocarditis",[1200,1221],"Rifampicin",{"trials":1223,"activeCount":99},[],{"trials":1225,"activeCount":99},[],{"intervention":1221,"totalTrials":95,"cells":1227},{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1232,"PHASE3":1234,"PHASE4":1240,"NA":1242},{"trials":1229,"activeCount":99},[],{"trials":1231,"activeCount":99},[],{"trials":1233,"activeCount":99},[],{"trials":1235,"activeCount":99},[1236],{"nctId":1211,"briefTitle":1212,"status":172,"phases":1237,"primaryCompletion":1214,"completion":1215,"start":1216,"enrollment":1217,"conditions":1238,"interventions":1239},[89],[1219],[1200,1221],{"trials":1241,"activeCount":99},[],{"trials":1243,"activeCount":99},[],{"intervention":1245,"totalTrials":95,"cells":1246},"TOPICAL SIROLIMUS",{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1251,"PHASE3":1253,"PHASE4":1267,"NA":1269},{"trials":1248,"activeCount":99},[],{"trials":1250,"activeCount":99},[],{"trials":1252,"activeCount":99},[],{"trials":1254,"activeCount":99},[1255],{"nctId":1256,"briefTitle":1257,"status":1258,"phases":1259,"primaryCompletion":1260,"completion":1260,"start":1261,"enrollment":1262,"conditions":1263,"interventions":1265},"NCT01061853","Efficacy of Topical Rapamycin to Treat Chronic Erosive Oral Lichen","TERMINATED",[89],"2012-11","2008-02",76,[1264],"Oral Lichen Planus",[1245,1266],"TOPICAL BETAMETHASONE 0.05%",{"trials":1268,"activeCount":99},[],{"trials":1270,"activeCount":99},[],{"intervention":1266,"totalTrials":95,"cells":1272},{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1277,"PHASE3":1279,"PHASE4":1285,"NA":1287},{"trials":1274,"activeCount":99},[],{"trials":1276,"activeCount":99},[],{"trials":1278,"activeCount":99},[],{"trials":1280,"activeCount":99},[1281],{"nctId":1256,"briefTitle":1257,"status":1258,"phases":1282,"primaryCompletion":1260,"completion":1260,"start":1261,"enrollment":1262,"conditions":1283,"interventions":1284},[89],[1264],[1245,1266],{"trials":1286,"activeCount":99},[],{"trials":1288,"activeCount":99},[],{"intervention":1290,"totalTrials":95,"cells":1291},"Spacing of Eculizumab infusions",{"EARLY_PHASE1":1292,"PHASE1":1294,"PHASE2":1296,"PHASE3":1298,"PHASE4":1310,"NA":1312},{"trials":1293,"activeCount":99},[],{"trials":1295,"activeCount":99},[],{"trials":1297,"activeCount":99},[],{"trials":1299,"activeCount":99},[1300],{"nctId":1301,"briefTitle":1302,"status":172,"phases":1303,"primaryCompletion":1304,"completion":1305,"start":1306,"enrollment":176,"conditions":1307,"interventions":1309},"NCT04859608","Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU)",[89],"2022-06-16","2023-12-28","2021-10-20",[1308],"Hemolytic-Uremic Syndrome, Atypical",[1290],{"trials":1311,"activeCount":99},[],{"trials":1313,"activeCount":99},[],{"intervention":1315,"totalTrials":95,"cells":1316},"triple therapy",{"EARLY_PHASE1":1317,"PHASE1":1319,"PHASE2":1321,"PHASE3":1323,"PHASE4":1337,"NA":1339},{"trials":1318,"activeCount":99},[],{"trials":1320,"activeCount":99},[],{"trials":1322,"activeCount":99},[],{"trials":1324,"activeCount":99},[1325],{"nctId":1326,"briefTitle":1327,"status":172,"phases":1328,"primaryCompletion":1329,"completion":1330,"start":1331,"enrollment":1332,"conditions":1333,"interventions":1335},"NCT02302547","Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy",[89],"2017-08-23","2018-09-21","2014-12",224,[1334],"HIV",[1315,1336],"dual therapy",{"trials":1338,"activeCount":99},[],{"trials":1340,"activeCount":99},[],{"intervention":1336,"totalTrials":95,"cells":1342},{"EARLY_PHASE1":1343,"PHASE1":1345,"PHASE2":1347,"PHASE3":1349,"PHASE4":1355,"NA":1357},{"trials":1344,"activeCount":99},[],{"trials":1346,"activeCount":99},[],{"trials":1348,"activeCount":99},[],{"trials":1350,"activeCount":99},[1351],{"nctId":1326,"briefTitle":1327,"status":172,"phases":1352,"primaryCompletion":1329,"completion":1330,"start":1331,"enrollment":1332,"conditions":1353,"interventions":1354},[89],[1334],[1315,1336],{"trials":1356,"activeCount":99},[],{"trials":1358,"activeCount":99},[],{"intervention":240,"totalTrials":95,"cells":1360},{"EARLY_PHASE1":1361,"PHASE1":1363,"PHASE2":1365,"PHASE3":1367,"PHASE4":1373,"NA":1375},{"trials":1362,"activeCount":99},[],{"trials":1364,"activeCount":99},[],{"trials":1366,"activeCount":99},[],{"trials":1368,"activeCount":99},[1369],{"nctId":230,"briefTitle":231,"status":172,"phases":1370,"primaryCompletion":233,"completion":234,"start":235,"enrollment":236,"conditions":1371,"interventions":1372},[89],[238],[55,240],{"trials":1374,"activeCount":99},[],{"trials":1376,"activeCount":99},[],{"intervention":1378,"totalTrials":95,"cells":1379},"Inhaled amikacin",{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1386,"PHASE4":1400,"NA":1402},{"trials":1381,"activeCount":99},[],{"trials":1383,"activeCount":99},[],{"trials":1385,"activeCount":99},[],{"trials":1387,"activeCount":99},[1388],{"nctId":1389,"briefTitle":1390,"status":172,"phases":1391,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":1395,"conditions":1396,"interventions":1398},"NCT03149640","Study Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia",[89],"2021-03-09","2021-06-17","2017-07-19",850,[1397],"Pneumonia, Ventilator-Associated",[1378,1399],"Inhaled placebo",{"trials":1401,"activeCount":99},[],{"trials":1403,"activeCount":99},[],{"intervention":1399,"totalTrials":95,"cells":1405},{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1410,"PHASE3":1412,"PHASE4":1418,"NA":1420},{"trials":1407,"activeCount":99},[],{"trials":1409,"activeCount":99},[],{"trials":1411,"activeCount":99},[],{"trials":1413,"activeCount":99},[1414],{"nctId":1389,"briefTitle":1390,"status":172,"phases":1415,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":1395,"conditions":1416,"interventions":1417},[89],[1397],[1378,1399],{"trials":1419,"activeCount":99},[],{"trials":1421,"activeCount":99},[],{"intervention":1423,"totalTrials":95,"cells":1424},"Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma",{"EARLY_PHASE1":1425,"PHASE1":1427,"PHASE2":1429,"PHASE3":1431,"PHASE4":1443,"NA":1445},{"trials":1426,"activeCount":99},[],{"trials":1428,"activeCount":99},[],{"trials":1430,"activeCount":99},[],{"trials":1432,"activeCount":99},[1433],{"nctId":1434,"briefTitle":1435,"status":172,"phases":1436,"primaryCompletion":1437,"completion":1438,"start":1095,"enrollment":11,"conditions":1439,"interventions":1442},"NCT04214444","Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab",[89],"2024-05-14","2025-05-14",[1440,1441],"Pneumococcal Infections","Lymphoma, Large B-Cell, Diffuse",[1423],{"trials":1444,"activeCount":99},[],{"trials":1446,"activeCount":99},[],{"intervention":1099,"totalTrials":95,"cells":1448},{"EARLY_PHASE1":1449,"PHASE1":1451,"PHASE2":1453,"PHASE3":1455,"PHASE4":1461,"NA":1463},{"trials":1450,"activeCount":99},[],{"trials":1452,"activeCount":99},[],{"trials":1454,"activeCount":99},[],{"trials":1456,"activeCount":99},[1457],{"nctId":1091,"briefTitle":1092,"status":1093,"phases":1458,"primaryCompletion":1095,"completion":1095,"start":1095,"enrollment":99,"conditions":1459,"interventions":1460},[89],[1097],[1099,1069],{"trials":1462,"activeCount":99},[],{"trials":1464,"activeCount":99},[],{"intervention":1063,"totalTrials":95,"cells":1466},{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1471,"PHASE3":1473,"PHASE4":1479,"NA":1481},{"trials":1468,"activeCount":99},[],{"trials":1470,"activeCount":99},[],{"trials":1472,"activeCount":99},[],{"trials":1474,"activeCount":99},[1475],{"nctId":1057,"briefTitle":1047,"status":172,"phases":1476,"primaryCompletion":1059,"completion":1059,"start":1050,"enrollment":176,"conditions":1477,"interventions":1478},[89],[1061],[1035,1063],{"trials":1480,"activeCount":99},[],{"trials":1482,"activeCount":99},[],{"intervention":1484,"totalTrials":95,"cells":1485},"Anakinra plus oSOC",{"EARLY_PHASE1":1486,"PHASE1":1488,"PHASE2":1490,"PHASE3":1492,"PHASE4":1508,"NA":1510},{"trials":1487,"activeCount":99},[],{"trials":1489,"activeCount":99},[],{"trials":1491,"activeCount":99},[],{"trials":1493,"activeCount":99},[1494],{"nctId":1495,"briefTitle":1496,"status":1258,"phases":1497,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":1502,"interventions":1506},"NCT04364009","Anakinra for COVID-19 Respiratory Symptoms",[89],"2020-10-20","2020-11-03","2020-04-27",71,[1503,1504,1505],"COVID-19 Infection","ANAKINRA Treatment","Optimized Standard of Care (oSOC)",[1484,1507],"oSOC",{"trials":1509,"activeCount":99},[],{"trials":1511,"activeCount":99},[],{"intervention":1507,"totalTrials":95,"cells":1513},{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1518,"PHASE3":1520,"PHASE4":1526,"NA":1528},{"trials":1515,"activeCount":99},[],{"trials":1517,"activeCount":99},[],{"trials":1519,"activeCount":99},[],{"trials":1521,"activeCount":99},[1522],{"nctId":1495,"briefTitle":1496,"status":1258,"phases":1523,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":1524,"interventions":1525},[89],[1503,1504,1505],[1484,1507],{"trials":1527,"activeCount":99},[],{"trials":1529,"activeCount":99},[],{"intervention":1531,"totalTrials":95,"cells":1532},"Cholecalciferol 100 000 UI",{"EARLY_PHASE1":1533,"PHASE1":1535,"PHASE2":1537,"PHASE3":1539,"PHASE4":1552,"NA":1554},{"trials":1534,"activeCount":99},[],{"trials":1536,"activeCount":99},[],{"trials":1538,"activeCount":99},[],{"trials":1540,"activeCount":99},[1541],{"nctId":1542,"briefTitle":1543,"status":172,"phases":1544,"primaryCompletion":1545,"completion":1545,"start":1546,"enrollment":1547,"conditions":1548,"interventions":1551},"NCT02185222","Effect of Vitamin D on Cognitive Decline of Patients With Memory Complaint",[89],"2018-10-10","2014-10-23",68,[1549,1550],"Memory Disorders","Age-Related Cognitive Decline",[1531],{"trials":1553,"activeCount":99},[],{"trials":1555,"activeCount":99},[],{"intervention":1557,"totalTrials":95,"cells":1558},"Amoxicillin",{"EARLY_PHASE1":1559,"PHASE1":1561,"PHASE2":1563,"PHASE3":1565,"PHASE4":1576,"NA":1578},{"trials":1560,"activeCount":99},[],{"trials":1562,"activeCount":99},[],{"trials":1564,"activeCount":99},[],{"trials":1566,"activeCount":99},[1567],{"nctId":1568,"briefTitle":1569,"status":172,"phases":1570,"primaryCompletion":1571,"completion":1572,"start":1216,"enrollment":1573,"conditions":1574,"interventions":1575},"NCT02701595","Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus",[89],"2023-02-24","2023-06-24",324,[1219],[1557],{"trials":1577,"activeCount":99},[],{"trials":1579,"activeCount":99},[],{"intervention":1581,"totalTrials":95,"cells":1582},"Iohexol",{"EARLY_PHASE1":1583,"PHASE1":1585,"PHASE2":1587,"PHASE3":1589,"PHASE4":1600,"NA":1602},{"trials":1584,"activeCount":99},[],{"trials":1586,"activeCount":99},[],{"trials":1588,"activeCount":99},[],{"trials":1590,"activeCount":99},[1591],{"nctId":1592,"briefTitle":1593,"status":172,"phases":1594,"primaryCompletion":1595,"completion":1595,"start":1596,"enrollment":571,"conditions":1597,"interventions":1599},"NCT02050269","Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study",[89],"2016-06","2014-01",[1598],"Acute Circulatory Failure",[1581],{"trials":1601,"activeCount":99},[],{"trials":1603,"activeCount":99},[],{"intervention":1605,"totalTrials":95,"cells":1606},"[18F]T807 PET",{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1611,"PHASE3":1624,"PHASE4":1626,"NA":1628},{"trials":1608,"activeCount":99},[],{"trials":1610,"activeCount":99},[],{"trials":1612,"activeCount":99},[1613],{"nctId":1614,"briefTitle":1615,"status":172,"phases":1616,"primaryCompletion":1617,"completion":1618,"start":1619,"enrollment":1620,"conditions":1621,"interventions":1623},"NCT03022968","Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD)",[88],"2019-08-27","2019-11-25","2017-01-10",17,[28,1622],"Benson's Disease",[1605],{"trials":1625,"activeCount":99},[],{"trials":1627,"activeCount":99},[],{"trials":1629,"activeCount":99},[],{"intervention":1631,"totalTrials":95,"cells":1632},"Sirolimus",{"EARLY_PHASE1":1633,"PHASE1":1635,"PHASE2":1637,"PHASE3":1649,"PHASE4":1651,"NA":1653},{"trials":1634,"activeCount":99},[],{"trials":1636,"activeCount":99},[],{"trials":1638,"activeCount":99},[1639],{"nctId":1640,"briefTitle":1641,"status":172,"phases":1642,"primaryCompletion":1643,"completion":1643,"start":1644,"enrollment":1645,"conditions":1646,"interventions":1648},"NCT02509468","suPERficial Slow-flow Vascular malFORMations Treated With sirolimUS",[88],"2019-03","2015-09-30",63,[1647],"Vascular Malformation",[1631],{"trials":1650,"activeCount":99},[],{"trials":1652,"activeCount":99},[],{"trials":1654,"activeCount":99},[],{"intervention":1656,"totalTrials":95,"cells":1657},"VANCOMYCIN",{"EARLY_PHASE1":1658,"PHASE1":1660,"PHASE2":1662,"PHASE3":1678,"PHASE4":1680,"NA":1682},{"trials":1659,"activeCount":99},[],{"trials":1661,"activeCount":99},[],{"trials":1663,"activeCount":99},[1664],{"nctId":1665,"briefTitle":1666,"status":621,"phases":1667,"primaryCompletion":1668,"completion":1668,"start":1059,"enrollment":571,"conditions":1669,"interventions":1671},"NCT01757236","Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection",[88],"2016-04",[1670],"Hip Prosthetic Joint Infection",[1656,1672,1673,1674,1675,1676,1677],"CEFTRIAXONE","CLINDAMYCIN","SULFAMETHOXAZOLE AND TRIMETHOPRIM","FLUOROQUINOLONE","LINEZOLID","RIFAMPIN",{"trials":1679,"activeCount":99},[],{"trials":1681,"activeCount":99},[],{"trials":1683,"activeCount":99},[],{"intervention":1672,"totalTrials":95,"cells":1685},{"EARLY_PHASE1":1686,"PHASE1":1688,"PHASE2":1690,"PHASE3":1696,"PHASE4":1698,"NA":1700},{"trials":1687,"activeCount":99},[],{"trials":1689,"activeCount":99},[],{"trials":1691,"activeCount":99},[1692],{"nctId":1665,"briefTitle":1666,"status":621,"phases":1693,"primaryCompletion":1668,"completion":1668,"start":1059,"enrollment":571,"conditions":1694,"interventions":1695},[88],[1670],[1656,1672,1673,1674,1675,1676,1677],{"trials":1697,"activeCount":99},[],{"trials":1699,"activeCount":99},[],{"trials":1701,"activeCount":99},[],{"intervention":1673,"totalTrials":95,"cells":1703},{"EARLY_PHASE1":1704,"PHASE1":1706,"PHASE2":1708,"PHASE3":1714,"PHASE4":1716,"NA":1718},{"trials":1705,"activeCount":99},[],{"trials":1707,"activeCount":99},[],{"trials":1709,"activeCount":99},[1710],{"nctId":1665,"briefTitle":1666,"status":621,"phases":1711,"primaryCompletion":1668,"completion":1668,"start":1059,"enrollment":571,"conditions":1712,"interventions":1713},[88],[1670],[1656,1672,1673,1674,1675,1676,1677],{"trials":1715,"activeCount":99},[],{"trials":1717,"activeCount":99},[],{"trials":1719,"activeCount":99},[],{"intervention":1674,"totalTrials":95,"cells":1721},{"EARLY_PHASE1":1722,"PHASE1":1724,"PHASE2":1726,"PHASE3":1732,"PHASE4":1734,"NA":1736},{"trials":1723,"activeCount":99},[],{"trials":1725,"activeCount":99},[],{"trials":1727,"activeCount":99},[1728],{"nctId":1665,"briefTitle":1666,"status":621,"phases":1729,"primaryCompletion":1668,"completion":1668,"start":1059,"enrollment":571,"conditions":1730,"interventions":1731},[88],[1670],[1656,1672,1673,1674,1675,1676,1677],{"trials":1733,"activeCount":99},[],{"trials":1735,"activeCount":99},[],{"trials":1737,"activeCount":99},[],{"intervention":1675,"totalTrials":95,"cells":1739},{"EARLY_PHASE1":1740,"PHASE1":1742,"PHASE2":1744,"PHASE3":1750,"PHASE4":1752,"NA":1754},{"trials":1741,"activeCount":99},[],{"trials":1743,"activeCount":99},[],{"trials":1745,"activeCount":99},[1746],{"nctId":1665,"briefTitle":1666,"status":621,"phases":1747,"primaryCompletion":1668,"completion":1668,"start":1059,"enrollment":571,"conditions":1748,"interventions":1749},[88],[1670],[1656,1672,1673,1674,1675,1676,1677],{"trials":1751,"activeCount":99},[],{"trials":1753,"activeCount":99},[],{"trials":1755,"activeCount":99},[],{"intervention":1676,"totalTrials":95,"cells":1757},{"EARLY_PHASE1":1758,"PHASE1":1760,"PHASE2":1762,"PHASE3":1768,"PHASE4":1770,"NA":1772},{"trials":1759,"activeCount":99},[],{"trials":1761,"activeCount":99},[],{"trials":1763,"activeCount":99},[1764],{"nctId":1665,"briefTitle":1666,"status":621,"phases":1765,"primaryCompletion":1668,"completion":1668,"start":1059,"enrollment":571,"conditions":1766,"interventions":1767},[88],[1670],[1656,1672,1673,1674,1675,1676,1677],{"trials":1769,"activeCount":99},[],{"trials":1771,"activeCount":99},[],{"trials":1773,"activeCount":99},[],{"intervention":1677,"totalTrials":95,"cells":1775},{"EARLY_PHASE1":1776,"PHASE1":1778,"PHASE2":1780,"PHASE3":1786,"PHASE4":1788,"NA":1790},{"trials":1777,"activeCount":99},[],{"trials":1779,"activeCount":99},[],{"trials":1781,"activeCount":99},[1782],{"nctId":1665,"briefTitle":1666,"status":621,"phases":1783,"primaryCompletion":1668,"completion":1668,"start":1059,"enrollment":571,"conditions":1784,"interventions":1785},[88],[1670],[1656,1672,1673,1674,1675,1676,1677],{"trials":1787,"activeCount":99},[],{"trials":1789,"activeCount":99},[],{"trials":1791,"activeCount":99},[],{"intervention":1793,"totalTrials":95,"cells":1794},"Topical 0.1% Sirolimus",{"EARLY_PHASE1":1795,"PHASE1":1797,"PHASE2":1799,"PHASE3":1813,"PHASE4":1815,"NA":1817},{"trials":1796,"activeCount":99},[],{"trials":1798,"activeCount":99},[],{"trials":1800,"activeCount":99},[1801],{"nctId":1802,"briefTitle":1803,"status":172,"phases":1804,"primaryCompletion":1805,"completion":1805,"start":1806,"enrollment":1807,"conditions":1808,"interventions":1811},"NCT03972592","Topical Sirolimus in Cutaneous Lymphatic Malformations",[88],"2024-08-14","2019-06-05",55,[1809,1810],"Vascular Malformations","Lymphatic Malformation",[1793,1812],"Topical Vehicle",{"trials":1814,"activeCount":99},[],{"trials":1816,"activeCount":99},[],{"trials":1818,"activeCount":99},[],{"intervention":1812,"totalTrials":95,"cells":1820},{"EARLY_PHASE1":1821,"PHASE1":1823,"PHASE2":1825,"PHASE3":1831,"PHASE4":1833,"NA":1835},{"trials":1822,"activeCount":99},[],{"trials":1824,"activeCount":99},[],{"trials":1826,"activeCount":99},[1827],{"nctId":1802,"briefTitle":1803,"status":172,"phases":1828,"primaryCompletion":1805,"completion":1805,"start":1806,"enrollment":1807,"conditions":1829,"interventions":1830},[88],[1809,1810],[1793,1812],{"trials":1832,"activeCount":99},[],{"trials":1834,"activeCount":99},[],{"trials":1836,"activeCount":99},[],{"intervention":1838,"totalTrials":95,"cells":1839},"Sonoporation",{"EARLY_PHASE1":1840,"PHASE1":1842,"PHASE2":1844,"PHASE3":1856,"PHASE4":1858,"NA":1860},{"trials":1841,"activeCount":99},[],{"trials":1843,"activeCount":99},[],{"trials":1845,"activeCount":99},[1846],{"nctId":1847,"briefTitle":1848,"status":172,"phases":1849,"primaryCompletion":1850,"completion":1850,"start":1851,"enrollment":16,"conditions":1852,"interventions":1855},"NCT03458975","Targeted Delivery of Chemotherapy With Ultrasound and Microbublles",[88],"2022-09-30","2019-10-01",[1853,1854],"Colorectal Cancer","Hepatic Metastases",[1838],{"trials":1857,"activeCount":99},[],{"trials":1859,"activeCount":99},[],{"trials":1861,"activeCount":99},[],{"intervention":1863,"totalTrials":95,"cells":1864},"Intravenous Levetiracetam",{"EARLY_PHASE1":1865,"PHASE1":1867,"PHASE2":1869,"PHASE3":1881,"PHASE4":1883,"NA":1885},{"trials":1866,"activeCount":99},[],{"trials":1868,"activeCount":99},[],{"trials":1870,"activeCount":99},[1871],{"nctId":1872,"briefTitle":1873,"status":172,"phases":1874,"primaryCompletion":1875,"completion":1875,"start":1876,"enrollment":1877,"conditions":1878,"interventions":1880},"NCT02229123","Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study",[88],"2022-02-23","2018-02-27",18,[1879],"Neonatal Seizures",[1863],{"trials":1882,"activeCount":99},[],{"trials":1884,"activeCount":99},[],{"trials":1886,"activeCount":99},[],{"intervention":1888,"totalTrials":95,"cells":1889},"Salbutamol",{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1894,"PHASE3":1906,"PHASE4":1908,"NA":1910},{"trials":1891,"activeCount":99},[],{"trials":1893,"activeCount":99},[],{"trials":1895,"activeCount":99},[1896],{"nctId":1897,"briefTitle":1898,"status":172,"phases":1899,"primaryCompletion":1900,"completion":1900,"start":1901,"enrollment":1902,"conditions":1903,"interventions":1905},"NCT01958814","Beta Agonist Nebulization in Non Invasively Ventilated COPD Patients: Safety, and Therapeutic Efficacy Range.",[88],"2015-07","2012-02",43,[1904],"Chronic Respiratory Failure",[1888],{"trials":1907,"activeCount":99},[],{"trials":1909,"activeCount":99},[],{"trials":1911,"activeCount":99},[],{"intervention":629,"totalTrials":95,"cells":1913},{"EARLY_PHASE1":1914,"PHASE1":1916,"PHASE2":1918,"PHASE3":1924,"PHASE4":1926,"NA":1928},{"trials":1915,"activeCount":99},[],{"trials":1917,"activeCount":99},[],{"trials":1919,"activeCount":99},[1920],{"nctId":619,"briefTitle":620,"status":621,"phases":1921,"primaryCompletion":39,"completion":623,"start":613,"enrollment":136,"conditions":1922,"interventions":1923},[88],[625,626,627],[629,603],{"trials":1925,"activeCount":99},[],{"trials":1927,"activeCount":99},[],{"trials":1929,"activeCount":99},[],{"intervention":1931,"totalTrials":95,"cells":1932},"Sirolimus Oral Liquid Product 1mg\u002FmL",{"EARLY_PHASE1":1933,"PHASE1":1935,"PHASE2":1937,"PHASE3":1949,"PHASE4":1951,"NA":1953},{"trials":1934,"activeCount":99},[],{"trials":1936,"activeCount":99},[],{"trials":1938,"activeCount":99},[1939],{"nctId":1940,"briefTitle":1941,"status":172,"phases":1942,"primaryCompletion":1943,"completion":1943,"start":1944,"enrollment":1945,"conditions":1946,"interventions":1948},"NCT04128722","TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN",[88],"2025-01-08","2020-02-14",12,[1947],"Lingual Microcystic Lymphatic Malformations",[1931],{"trials":1950,"activeCount":99},[],{"trials":1952,"activeCount":99},[],{"trials":1954,"activeCount":99},[],{"intervention":1956,"totalTrials":95,"cells":1957},"[18F]FPEB PET imaging",{"EARLY_PHASE1":1958,"PHASE1":1960,"PHASE2":1974,"PHASE3":1976,"PHASE4":1978,"NA":1980},{"trials":1959,"activeCount":99},[],{"trials":1961,"activeCount":99},[1962],{"nctId":1963,"briefTitle":1964,"status":172,"phases":1965,"primaryCompletion":1966,"completion":1967,"start":1668,"enrollment":1968,"conditions":1969,"interventions":1973},"NCT02719951","Glutaminergic Transmission in Autism : Molecular Imaging Exploration",[87],"2018-11-15","2019-05",27,[1970,1971,1972],"Autism","Fragile-X Syndrome (FXS)","Healthy Volunteers",[1956],{"trials":1975,"activeCount":99},[],{"trials":1977,"activeCount":99},[],{"trials":1979,"activeCount":99},[],{"trials":1981,"activeCount":99},[],{"intervention":1983,"totalTrials":95,"cells":1984},"[18F]DPA-714 PET\u002F [18F]AV-45 PET\u002Fneuropsychological assessment",{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":1999,"PHASE3":2001,"PHASE4":2003,"NA":2005},{"trials":1986,"activeCount":99},[],{"trials":1988,"activeCount":99},[1989],{"nctId":1990,"briefTitle":1991,"status":172,"phases":1992,"primaryCompletion":1993,"completion":1993,"start":1596,"enrollment":1994,"conditions":1995,"interventions":1998},"NCT02062099","PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)",[87],"2018-05-22",25,[1996,1997,28],"Memory Complaint","Mild Cognitive Impairment",[1983],{"trials":2000,"activeCount":99},[],{"trials":2002,"activeCount":99},[],{"trials":2004,"activeCount":99},[],{"trials":2006,"activeCount":99},[],{"intervention":2008,"totalTrials":95,"cells":2009},"[18F]DPA-714 PET",{"EARLY_PHASE1":2010,"PHASE1":2020,"PHASE2":2022,"PHASE3":2024,"PHASE4":2026,"NA":2028},{"trials":2011,"activeCount":99},[2012],{"nctId":2013,"briefTitle":2014,"status":1093,"phases":2015,"primaryCompletion":2016,"completion":2017,"start":816,"enrollment":99,"conditions":2018,"interventions":2019},"NCT02405403","Microglial Activation Role In ALS (MARIA)",[86],"2016-09","2017-03",[15],[2008],{"trials":2021,"activeCount":99},[],{"trials":2023,"activeCount":99},[],{"trials":2025,"activeCount":99},[],{"trials":2027,"activeCount":99},[],{"trials":2029,"activeCount":99},[],{"intervention":2031,"totalTrials":95,"cells":2032},"[18F] LBT-999 PET",{"EARLY_PHASE1":2033,"PHASE1":2045,"PHASE2":2047,"PHASE3":2049,"PHASE4":2051,"NA":2053},{"trials":2034,"activeCount":99},[2035],{"nctId":2036,"briefTitle":2037,"status":1258,"phases":2038,"primaryCompletion":2039,"completion":2040,"start":816,"enrollment":2041,"conditions":2042,"interventions":2044},"NCT02393027","Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999",[86],"2016-11","2017-05",16,[2043],"Idiopathic Parkinson Disease",[2031],{"trials":2046,"activeCount":99},[],{"trials":2048,"activeCount":99},[],{"trials":2050,"activeCount":99},[],{"trials":2052,"activeCount":99},[],{"trials":2054,"activeCount":99},[],{"intervention":2056,"totalTrials":34,"cells":2057},"adalimumab",{"EARLY_PHASE1":2058,"PHASE1":2060,"PHASE2":2062,"PHASE3":2064,"PHASE4":2066,"NA":2080},{"trials":2059,"activeCount":99},[],{"trials":2061,"activeCount":99},[],{"trials":2063,"activeCount":99},[],{"trials":2065,"activeCount":99},[],{"trials":2067,"activeCount":99},[2068,2076],{"nctId":2069,"briefTitle":2070,"status":172,"phases":2071,"primaryCompletion":817,"completion":817,"start":2072,"enrollment":2073,"conditions":2074,"interventions":2075},"NCT01382160","Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)",[90],"2011-01",69,[21],[2056],{"nctId":970,"briefTitle":971,"status":172,"phases":2077,"primaryCompletion":973,"completion":973,"start":974,"enrollment":975,"conditions":2078,"interventions":2079},[90],[977],[979,957],{"trials":2081,"activeCount":99},[2082],{"nctId":2083,"briefTitle":2084,"status":172,"phases":2085,"primaryCompletion":224,"completion":2086,"start":2087,"enrollment":2088,"conditions":2089,"interventions":2090},"NCT00497614","Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA)",[91],"2008-12","2006-05",8,[21],[2056],{"intervention":2092,"totalTrials":146,"cells":2093},"infliximab",{"EARLY_PHASE1":2094,"PHASE1":2096,"PHASE2":2098,"PHASE3":2100,"PHASE4":2102,"NA":2113},{"trials":2095,"activeCount":99},[],{"trials":2097,"activeCount":99},[],{"trials":2099,"activeCount":99},[],{"trials":2101,"activeCount":99},[],{"trials":2103,"activeCount":99},[2104],{"nctId":2105,"briefTitle":2106,"status":172,"phases":2107,"primaryCompletion":2108,"completion":2109,"start":2110,"enrollment":136,"conditions":2111,"interventions":2112},"NCT00507403","Infliximab and Methotrexate in Ankylosing Spondylitis",[90],"2009-10","2009-12","2007-10",[977],[2092],{"trials":2114,"activeCount":99},[2115],{"nctId":2116,"briefTitle":2117,"status":172,"phases":2118,"primaryCompletion":2119,"completion":2119,"start":2120,"enrollment":2121,"conditions":2122,"interventions":2123},"NCT00840957","Pharmaco Kinetic Variability of Infliximab in Rheumatoid Arthritis",[],"2009-11","2007-11",84,[21],[2092],{"intervention":2125,"totalTrials":95,"cells":2126},"Nitrous Oxide-Oxygen",{"EARLY_PHASE1":2127,"PHASE1":2129,"PHASE2":2131,"PHASE3":2133,"PHASE4":2135,"NA":2137},{"trials":2128,"activeCount":99},[],{"trials":2130,"activeCount":99},[],{"trials":2132,"activeCount":99},[],{"trials":2134,"activeCount":99},[],{"trials":2136,"activeCount":99},[],{"trials":2138,"activeCount":99},[2139],{"nctId":2140,"briefTitle":2141,"status":172,"phases":2142,"primaryCompletion":2143,"completion":2143,"start":2144,"enrollment":136,"conditions":2145,"interventions":2148},"NCT04199143","Brain Reactivity to Nitrous Oxyde in Depression : an MRI and Ultrasound Study (PROTOBRAIN Pilote)",[91],"2021-06-10","2020-02-20",[2146,2147],"Treatment Resistant Depression","Nitrous Oxyde",[2125],{"intervention":2150,"totalTrials":95,"cells":2151},"Blood test for biological assessment of liver function",{"EARLY_PHASE1":2152,"PHASE1":2154,"PHASE2":2156,"PHASE3":2158,"PHASE4":2160,"NA":2162},{"trials":2153,"activeCount":99},[],{"trials":2155,"activeCount":99},[],{"trials":2157,"activeCount":99},[],{"trials":2159,"activeCount":99},[],{"trials":2161,"activeCount":99},[],{"trials":2163,"activeCount":99},[2164],{"nctId":2165,"briefTitle":2166,"status":621,"phases":2167,"primaryCompletion":2168,"completion":2168,"start":872,"enrollment":2169,"conditions":2170,"interventions":2172},"NCT02575625","Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis",[91],"2015-10",85,[2171],"Liver Steatosis",[2150],{"intervention":2174,"totalTrials":95,"cells":2175},"usual medical treatment",{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2180,"PHASE3":2182,"PHASE4":2184,"NA":2186},{"trials":2177,"activeCount":99},[],{"trials":2179,"activeCount":99},[],{"trials":2181,"activeCount":99},[],{"trials":2183,"activeCount":99},[],{"trials":2185,"activeCount":99},[],{"trials":2187,"activeCount":99},[2188],{"nctId":2189,"briefTitle":2190,"status":621,"phases":2191,"primaryCompletion":2192,"completion":2193,"start":2194,"enrollment":2195,"conditions":2196,"interventions":2197},"NCT04937309","Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea",[91],"2024-02-15","2024-05-01","2022-06-24",338,[18],[2174],{"intervention":2199,"totalTrials":95,"cells":2200},"Blood",{"EARLY_PHASE1":2201,"PHASE1":2203,"PHASE2":2205,"PHASE3":2207,"PHASE4":2209,"NA":2211},{"trials":2202,"activeCount":99},[],{"trials":2204,"activeCount":99},[],{"trials":2206,"activeCount":99},[],{"trials":2208,"activeCount":99},[],{"trials":2210,"activeCount":99},[],{"trials":2212,"activeCount":99},[2213],{"nctId":2214,"briefTitle":2215,"status":172,"phases":2216,"primaryCompletion":2217,"completion":2218,"start":2219,"enrollment":2220,"conditions":2221,"interventions":2222},"NCT04819555","Frequency of SOD1 and C9orf72 Gene Mutations in French ALS",[],"2022-03-31","2023-05-15","2021-04-30",1000,[15],[2199],{"intervention":2224,"totalTrials":95,"cells":2225},"Methoxyflurane",{"EARLY_PHASE1":2226,"PHASE1":2228,"PHASE2":2230,"PHASE3":2232,"PHASE4":2234,"NA":2236},{"trials":2227,"activeCount":99},[],{"trials":2229,"activeCount":99},[],{"trials":2231,"activeCount":99},[],{"trials":2233,"activeCount":99},[],{"trials":2235,"activeCount":99},[],{"trials":2237,"activeCount":99},[2238],{"nctId":2239,"briefTitle":2240,"status":172,"phases":2241,"primaryCompletion":2242,"completion":2242,"start":2243,"enrollment":549,"conditions":2244,"interventions":2247},"NCT03927729","Use of Methoxyflurane (Penthrox) as an Antalgic in Hospital Trauma",[91],"2020-03-11","2019-06-07",[2245,2246],"Pain","Traumatic Injury",[2224],{"intervention":2249,"totalTrials":95,"cells":2250},"Parenteral L-carnitine supplementation",{"EARLY_PHASE1":2251,"PHASE1":2253,"PHASE2":2255,"PHASE3":2257,"PHASE4":2259,"NA":2261},{"trials":2252,"activeCount":99},[],{"trials":2254,"activeCount":99},[],{"trials":2256,"activeCount":99},[],{"trials":2258,"activeCount":99},[],{"trials":2260,"activeCount":99},[],{"trials":2262,"activeCount":99},[2263],{"nctId":2264,"briefTitle":2265,"status":172,"phases":2266,"primaryCompletion":2267,"completion":817,"start":2268,"enrollment":2269,"conditions":2270,"interventions":2272},"NCT00841295","Effects of Parenteral L-carnitine Supplementation in Premature Neonates",[91],"2013-03","2008-07",53,[2271],"Complication of Prematurity",[2249,2273],"Parenteral supplementation with sterile water",{"intervention":2273,"totalTrials":95,"cells":2275},{"EARLY_PHASE1":2276,"PHASE1":2278,"PHASE2":2280,"PHASE3":2282,"PHASE4":2284,"NA":2286},{"trials":2277,"activeCount":99},[],{"trials":2279,"activeCount":99},[],{"trials":2281,"activeCount":99},[],{"trials":2283,"activeCount":99},[],{"trials":2285,"activeCount":99},[],{"trials":2287,"activeCount":99},[2288],{"nctId":2264,"briefTitle":2265,"status":172,"phases":2289,"primaryCompletion":2267,"completion":817,"start":2268,"enrollment":2269,"conditions":2290,"interventions":2291},[91],[2271],[2249,2273],{"intervention":2293,"totalTrials":95,"cells":2294},"Blood copeptin monitoring",{"EARLY_PHASE1":2295,"PHASE1":2297,"PHASE2":2299,"PHASE3":2301,"PHASE4":2303,"NA":2305},{"trials":2296,"activeCount":99},[],{"trials":2298,"activeCount":99},[],{"trials":2300,"activeCount":99},[],{"trials":2302,"activeCount":99},[],{"trials":2304,"activeCount":99},[],{"trials":2306,"activeCount":99},[2307],{"nctId":2308,"briefTitle":2309,"status":172,"phases":2310,"primaryCompletion":2311,"completion":2311,"start":2312,"enrollment":2313,"conditions":2314,"interventions":2316},"NCT04950270","Copeptin Kinetics in Critically Ill Patients With Posterior Reversible Encephalopathy Syndrome",[],"2024-02-26","2022-06-18",24,[2315],"Posterior Reversible Encephalopathy Syndrome",[2293],{"intervention":2318,"totalTrials":95,"cells":2319},"contast-enhanced ultrasound with sonovue",{"EARLY_PHASE1":2320,"PHASE1":2322,"PHASE2":2324,"PHASE3":2326,"PHASE4":2328,"NA":2330},{"trials":2321,"activeCount":99},[],{"trials":2323,"activeCount":99},[],{"trials":2325,"activeCount":99},[],{"trials":2327,"activeCount":99},[],{"trials":2329,"activeCount":99},[],{"trials":2331,"activeCount":99},[2332],{"nctId":2333,"briefTitle":2334,"status":172,"phases":2335,"primaryCompletion":1171,"completion":2336,"start":2337,"enrollment":2338,"conditions":2339,"interventions":2341},"NCT02302573","Placenta Accreta : Contrast-enhanced Ultrasound Analysis in High Risk Population",[91],"2016-08","2009-05",80,[2340],"Placenta Accreta",[2318],{"intervention":2343,"totalTrials":95,"cells":2344},"blood test",{"EARLY_PHASE1":2345,"PHASE1":2347,"PHASE2":2349,"PHASE3":2351,"PHASE4":2353,"NA":2355},{"trials":2346,"activeCount":99},[],{"trials":2348,"activeCount":99},[],{"trials":2350,"activeCount":99},[],{"trials":2352,"activeCount":99},[],{"trials":2354,"activeCount":99},[],{"trials":2356,"activeCount":99},[2357],{"nctId":2358,"briefTitle":2359,"status":172,"phases":2360,"primaryCompletion":2361,"completion":2361,"start":2362,"enrollment":692,"conditions":2363,"interventions":2364},"NCT03118193","Biomarkers of Antidepressant Resistance",[91],"2021-01-12","2017-06-16",[30],[2343,2365],"Collection of faeces",{"intervention":2365,"totalTrials":95,"cells":2367},{"EARLY_PHASE1":2368,"PHASE1":2370,"PHASE2":2372,"PHASE3":2374,"PHASE4":2376,"NA":2378},{"trials":2369,"activeCount":99},[],{"trials":2371,"activeCount":99},[],{"trials":2373,"activeCount":99},[],{"trials":2375,"activeCount":99},[],{"trials":2377,"activeCount":99},[],{"trials":2379,"activeCount":99},[2380],{"nctId":2358,"briefTitle":2359,"status":172,"phases":2381,"primaryCompletion":2361,"completion":2361,"start":2362,"enrollment":692,"conditions":2382,"interventions":2383},[91],[30],[2343,2365],{"intervention":2385,"totalTrials":95,"cells":2386},"Sampling",{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2391,"PHASE3":2393,"PHASE4":2395,"NA":2397},{"trials":2388,"activeCount":99},[],{"trials":2390,"activeCount":99},[],{"trials":2392,"activeCount":99},[],{"trials":2394,"activeCount":99},[],{"trials":2396,"activeCount":99},[],{"trials":2398,"activeCount":99},[2399],{"nctId":2400,"briefTitle":2401,"status":621,"phases":2402,"primaryCompletion":2403,"completion":2403,"start":2404,"enrollment":2405,"conditions":2406,"interventions":2408},"NCT06142279","Development and Qualification of Methods for Analyzing the Mucosal Immune Response to COVID-19",[91],"2024-11","2023-11",240,[2407],"Certain Disorders Involving the Immune Mechanism",[2385,2409],"PCR (polymerase chain reaction) SARS-CoV-2",{"intervention":2409,"totalTrials":95,"cells":2411},{"EARLY_PHASE1":2412,"PHASE1":2414,"PHASE2":2416,"PHASE3":2418,"PHASE4":2420,"NA":2422},{"trials":2413,"activeCount":99},[],{"trials":2415,"activeCount":99},[],{"trials":2417,"activeCount":99},[],{"trials":2419,"activeCount":99},[],{"trials":2421,"activeCount":99},[],{"trials":2423,"activeCount":99},[2424],{"nctId":2400,"briefTitle":2401,"status":621,"phases":2425,"primaryCompletion":2403,"completion":2403,"start":2404,"enrollment":2405,"conditions":2426,"interventions":2427},[91],[2407],[2385,2409],{"intervention":2429,"totalTrials":95,"cells":2430},"search for polymorphisms of RASA1 gene",{"EARLY_PHASE1":2431,"PHASE1":2433,"PHASE2":2435,"PHASE3":2437,"PHASE4":2439,"NA":2441},{"trials":2432,"activeCount":99},[],{"trials":2434,"activeCount":99},[],{"trials":2436,"activeCount":99},[],{"trials":2438,"activeCount":99},[],{"trials":2440,"activeCount":99},[],{"trials":2442,"activeCount":99},[2443],{"nctId":2444,"briefTitle":2445,"status":172,"phases":2446,"primaryCompletion":2447,"completion":2447,"start":2448,"enrollment":2449,"conditions":2450,"interventions":2454},"NCT01364857","French National Cohort of Children With Port Wine Stain",[91],"2019-11","2010-11",150,[2451,2452,2453],"Port Wine Stain","Klippel Trenaunay Syndrome","Parkes Weber Syndrome",[2429],{"intervention":2456,"totalTrials":95,"cells":2457},"18FAV45",{"EARLY_PHASE1":2458,"PHASE1":2460,"PHASE2":2462,"PHASE3":2464,"PHASE4":2466,"NA":2468},{"trials":2459,"activeCount":99},[],{"trials":2461,"activeCount":99},[],{"trials":2463,"activeCount":99},[],{"trials":2465,"activeCount":99},[],{"trials":2467,"activeCount":99},[],{"trials":2469,"activeCount":99},[2470],{"nctId":2471,"briefTitle":2472,"status":172,"phases":2473,"primaryCompletion":2474,"completion":2474,"start":2475,"enrollment":2476,"conditions":2477,"interventions":2480},"NCT01962753","Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP)",[91],"2020-01-22","2012-05-10",92,[2478,2479],"Elderly","Major Depression",[2456],{"intervention":2482,"totalTrials":95,"cells":2483},"analysis of the glutamate synapse in autism",{"EARLY_PHASE1":2484,"PHASE1":2486,"PHASE2":2488,"PHASE3":2490,"PHASE4":2492,"NA":2494},{"trials":2485,"activeCount":99},[],{"trials":2487,"activeCount":99},[],{"trials":2489,"activeCount":99},[],{"trials":2491,"activeCount":99},[],{"trials":2493,"activeCount":99},[],{"trials":2495,"activeCount":99},[2496],{"nctId":2497,"briefTitle":2498,"status":172,"phases":2499,"primaryCompletion":2072,"completion":2500,"start":2501,"enrollment":2502,"conditions":2503,"interventions":2504},"NCT01770548","Neurophysiological Molecular and Developmental Analysis of the Glutamate Synapse in Autism",[91],"2014-06","2009-01",497,[1970],[2482,2505],"DNA collection",{"intervention":2505,"totalTrials":95,"cells":2507},{"EARLY_PHASE1":2508,"PHASE1":2510,"PHASE2":2512,"PHASE3":2514,"PHASE4":2516,"NA":2518},{"trials":2509,"activeCount":99},[],{"trials":2511,"activeCount":99},[],{"trials":2513,"activeCount":99},[],{"trials":2515,"activeCount":99},[],{"trials":2517,"activeCount":99},[],{"trials":2519,"activeCount":99},[2520],{"nctId":2497,"briefTitle":2498,"status":172,"phases":2521,"primaryCompletion":2072,"completion":2500,"start":2501,"enrollment":2502,"conditions":2522,"interventions":2523},[91],[1970],[2482,2505],{"intervention":2525,"totalTrials":95,"cells":2526},"SonoVue",{"EARLY_PHASE1":2527,"PHASE1":2529,"PHASE2":2531,"PHASE3":2533,"PHASE4":2535,"NA":2537},{"trials":2528,"activeCount":99},[],{"trials":2530,"activeCount":99},[],{"trials":2532,"activeCount":99},[],{"trials":2534,"activeCount":99},[],{"trials":2536,"activeCount":99},[],{"trials":2538,"activeCount":99},[2539],{"nctId":2540,"briefTitle":2541,"status":172,"phases":2542,"completion":2543,"start":2544,"enrollment":2545,"conditions":2546,"interventions":2548},"NCT00243698","A Pilot Study Evaluation of the Efficacy of SonoVue to Detect and Characterise Breast Lesions",[91],"2007-05","2004-05",59,[2547],"Breast Tumors",[2525]]